Innate Pharma to present at H.C. Wainwright 2026

Innate Pharma’s Sept. 14, 2026 4:30 PM EDT fireside chat will be live webcast with replay available via its Investors section.

Rhea-AI Filing Summary

Innate Pharma S.A. (IPHA), a clinical-stage biotechnology company focused on immunotherapies for cancer, reported that members of its executive team will participate in the H.C. Wainwright 28th Annual Global Investment Conference in New York, United States, on September 14–16, 2026. A fireside chat is scheduled for September 14, 2026 at 4:30 PM EDT / 10:30 PM CEST, with a live webcast and replay accessible via the Investors section of Innate Pharma’s website. The company highlights a pipeline centered on antibody-drug conjugates, led by IPH4502 targeting Nectin-4 for solid tumors, alongside partnered late-stage assets lacutamab with Sobi for cutaneous T-cell lymphomas and monalizumab with AstraZeneca for non-small cell lung cancer.

Key Figures

Conference dates: September 14–16, 2026 Fireside chat time: 4:30 PM EDT / 10:30 PM CEST ISIN code: FR0010331421 +2 more

5 metrics

Conference dates September 14–16, 2026 H.C. Wainwright 28th Annual Global Investment Conference in New York, United States

Fireside chat time 4:30 PM EDT / 10:30 PM CEST Fireside chat on September 14, 2026 during the H.C. Wainwright conference

ISIN code FR0010331421 Identifier for Innate Pharma S.A. shares

Euronext ticker IPH Innate Pharma listing on Euronext Paris

Nasdaq ticker IPHA Innate Pharma listing on Nasdaq in the United States

Key Terms

antibody-drug conjugates (ADCs), Nectin-4, cutaneous T-cell lymphomas, non-small cell lung cancer (NSCLC), +1 more

5 terms

antibody-drug conjugates (ADCs) medical

"Its proprietary pipeline is centered on antibody-drug conjugates (ADCs), led by IPH4502"

Antibody-drug conjugates (ADCs) are advanced medicines that combine a targeted antibody with a powerful drug, acting like a guided missile to deliver treatment directly to cancer cells while sparing healthy tissue. This precision approach can improve effectiveness and reduce side effects, making ADCs a promising area of biotech innovation. For investors, advancements in ADC technology can signal potential growth opportunities in the pharmaceutical and healthcare sectors.

Nectin-4 medical

"IPH4502, a differentiated Nectin-4 ADC in clinical development for solid tumors"

A cell-surface protein that helps neighboring cells stick together and communicate; it is normally present during development but can become abundant on certain cancer cells. Investors pay attention because high levels make it a useful biomarker and a direct target for cancer therapies and diagnostic tests—similar to a distinctive flag on a building that lets a targeted treatment or test find and act on diseased tissue—affecting drug value, regulatory reviews, and market potential.

cutaneous T-cell lymphomas medical

"lacutamab, developed with Sobi for cutaneous T-cell lymphomas"

A group of rare non-Hodgkin lymphomas in which cancerous T-lymphocytes primarily grow in the skin, causing patches, plaques, nodules or tumors and sometimes spreading internally. Investors care because these chronic, often slow-progressing diseases create specialized markets for diagnostics, topical and systemic therapies, and clinical trials; trial results, regulatory decisions, and new treatment approvals can materially affect companies focused on cancer drugs and dermatology.

non-small cell lung cancer (NSCLC) medical

"monalizumab, developed with AstraZeneca for non-small cell lung cancer (NSCLC)"

A common group of lung cancers that arise from the lungs’ cell lining and grow in ways different from the faster-spreading “small cell” form; think of it as several related varieties of the same illness rather than one single disease. It matters to investors because diagnosis rates, new drugs, diagnostic tests, and clinical trial results for these cancers can drive large, sustained revenue opportunities and regulatory decisions that materially affect healthcare and biotech company valuations.

immunotherapies medical

"a clinical-stage biotechnology company developing immunotherapies for cancer patients"

Immunotherapies are medical treatments that strengthen or guide the body's own immune system to recognize and fight disease cells, such as cancer or chronic infections. They matter to investors because they can produce long-lasting patient responses, command premium prices, and reshape standard care—similar to installing a smarter security system that prevents repeat break-ins—creating significant commercial upside but also clinical and regulatory risk.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What event is Innate Pharma (IPHA) participating in according to this 6-K?

Innate Pharma will participate in the H.C. Wainwright 28th Annual Global Investment Conference in New York, United States, taking place from September 14–16, 2026, including a fireside chat and one-on-one investor meetings.

When is Innate Pharma’s (IPHA) fireside chat scheduled at the H.C. Wainwright conference?

The fireside chat is scheduled for September 14, 2026 at 4:30 PM EDT / 10:30 PM CEST. A live webcast will be accessible via the Events page in the Investors section of Innate Pharma’s website, with a replay available afterward.

How can investors access the Innate Pharma (IPHA) fireside chat webcast?

Investors can access the live webcast of the fireside chat through a link on the Events page of the Investors section of Innate Pharma’s website. A replay will be made available following the event.

What is the core focus of Innate Pharma’s (IPHA) proprietary pipeline?

Innate Pharma’s proprietary pipeline is centered on antibody-drug conjugates (ADCs), led by IPH4502, a Nectin-4 ADC in clinical development for solid tumors, alongside a preclinical portfolio of next-generation ADC candidates.

Which late-stage partnered assets does Innate Pharma (IPHA) highlight in this report?

Innate Pharma highlights two late-stage partnered assets: lacutamab, developed with Sobi for cutaneous T-cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer (NSCLC).

On which exchanges are Innate Pharma (IPHA) shares listed and what is the ISIN?

Innate Pharma shares are listed on Euronext Paris under ticker IPH and on Nasdaq under ticker IPHA. The ISIN code for Innate Pharma shares is FR0010331421.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 06:56 AM EDT Accepted by SEC EDGAR 09/02/2026 - 06:56 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of report: Wednesday September 2, 2026

Commission File Number: 001-39084

Innate Pharma S.A.

(Translation of registrant's name into English)

Innate Pharma S.A.

117 Avenue de Luminy—BP 30191

13009 Marseille, France

+ 33 (0) 4 30 30 30

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ]    Form 40-F [ ]

EXHIBIT INDEX

Exhibit Description

99.1 Press Release dated September 2, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

INNATE PHARMA S.A.

Date: September 2, 2026 By: /s/ JONATHAN DICKINSON Name: Jonathan Dickinson

Title:    Chief Executive officer

EXHIBIT 99.1

INNATE PHARMA TO PARTICIPATE IN THE H.C. WAINWRIGHT 28TH ANNUAL GLOBAL INVESTMENT CONFERENCE

Marseille, France, September 2, 2026, 7:00 AM CEST

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in a fireside chat and one-on-one investor meetings at the following conference:

H.C. Wainwright 28th Annual Global Investment Conference

Dates: September 14–16, 2026

Location: New York, United States

Fireside chat:

Date: September 14, 2026

Time: 4:30 PM EDT / 10:30 PM CEST

Webcast: Access the webcast

The link to access the live webcast of the fireside chat will also be available on the Events page of the Investors section of Innate Pharma’s website. A replay will be available following the event.

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise in antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next generation antibody therapeutics.

Innate Pharma is advancing a portfolio of differentiated potential first- and/or best-in-class assets, focused on areas of high unmet medical need. Its proprietary pipeline is centered on antibody-drug conjugates (ADCs), led by IPH4502, a differentiated Nectin-4 ADC in clinical development for solid tumors, and supported by a preclinical portfolio of next-generation ADC candidates. In parallel, Innate is advancing two partnered late-stage assets: lacutamab, developed with Sobi for cutaneous T-cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer (NSCLC).

Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sobi, Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.

Headquartered in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.

Information about Innate Pharma shares

ISIN code FR0010331421

Ticker code Euronext: IPH Nasdaq: IPHA

LEI    9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors

For a discussion of risks and uncertainties, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

Contacts

Stéphanie Cornen

VP, Investor Relations & Corporate Communications

stephanie.cornen@innate-pharma.fr

Investor Relations

investors@innate-pharma.fr

Media

communication@innate-pharma.fr        

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 11.2 KB